{"title":"dupilumab治疗严重哮喘的进展","authors":"Jia Li, Lun Li","doi":"10.3760/CMA.J.ISSN.1673-436X.2020.05.010","DOIUrl":null,"url":null,"abstract":"Bronchial asthma (asthma) is such a chronic airway inflammatory disease which mediated by T helper cell type 2 (Th2). The Th2 cells secret interleukin-4 (IL-4) and IL-13, which activate the downstream signal transduction through the co-receptor interleukin-4 receptor α(IL-4Rα). Dupilumab is a fully human anti-IL-4 Rα monoclonal antibody that competitive inhibits the combination between IL-4Rα and IL-4 or IL-13, which can reduce severe exacerbation and increased lung function in patients with severe asthma.The update of the efficacy and safety of dupilumab for treating severe asthma is reviewed in this article. \n \n \nKey words: \nAsthma; Antibodies, monoclonal; Dupilumab","PeriodicalId":10004,"journal":{"name":"Chinese Journal of Asthma","volume":"2016 1","pages":"378-381"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progress in the treatment of severe asthma with dupilumab\",\"authors\":\"Jia Li, Lun Li\",\"doi\":\"10.3760/CMA.J.ISSN.1673-436X.2020.05.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bronchial asthma (asthma) is such a chronic airway inflammatory disease which mediated by T helper cell type 2 (Th2). The Th2 cells secret interleukin-4 (IL-4) and IL-13, which activate the downstream signal transduction through the co-receptor interleukin-4 receptor α(IL-4Rα). Dupilumab is a fully human anti-IL-4 Rα monoclonal antibody that competitive inhibits the combination between IL-4Rα and IL-4 or IL-13, which can reduce severe exacerbation and increased lung function in patients with severe asthma.The update of the efficacy and safety of dupilumab for treating severe asthma is reviewed in this article. \\n \\n \\nKey words: \\nAsthma; Antibodies, monoclonal; Dupilumab\",\"PeriodicalId\":10004,\"journal\":{\"name\":\"Chinese Journal of Asthma\",\"volume\":\"2016 1\",\"pages\":\"378-381\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese Journal of Asthma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-436X.2020.05.010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Asthma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-436X.2020.05.010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Progress in the treatment of severe asthma with dupilumab
Bronchial asthma (asthma) is such a chronic airway inflammatory disease which mediated by T helper cell type 2 (Th2). The Th2 cells secret interleukin-4 (IL-4) and IL-13, which activate the downstream signal transduction through the co-receptor interleukin-4 receptor α(IL-4Rα). Dupilumab is a fully human anti-IL-4 Rα monoclonal antibody that competitive inhibits the combination between IL-4Rα and IL-4 or IL-13, which can reduce severe exacerbation and increased lung function in patients with severe asthma.The update of the efficacy and safety of dupilumab for treating severe asthma is reviewed in this article.
Key words:
Asthma; Antibodies, monoclonal; Dupilumab
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
